Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages.
We believe it doesn’t have to be this way.
Assembled a deep clinical evidence library with data collected from more than 1,200 subjects
More than 20 premier cancer institutions around the world participated in our clinical trials
IONIQ's ProLung Test was awarded “Breakthrough Device Designation” by US FDA for its life-enhancing potential
Robust, growing intellectual portfolio of patents and know-how
IONIQ Sciences awarded another patent for “an apparatus for providing information that is useful in the diagnosis of a malignant lung lesion” IONIQ’s newest Notice of Allowance by the State Intellectual Property Office of the People’s Republic of China (SIPO) covers critical advancements and refinements
BIO has just now announced that IONIQ Sciences is a finalist for their prestigious ‘Buzz of BIO 2021’ award. Please click HERE to vote for IONIQ Sciences in the ‘Diagnostics and Beyond’ category! Just click “Vote for this Company” and take 30 seconds to set up a voting profile. Voting closes
IONIQ has been awarded the 2020 Business Excellence Award by Silicon Review. We’re proud of the progress we made last year in our pursuit of a point-of-care (POC) screening device to help counter this nation’s second leading cause of death. Cancer killed more than 600,000 Americans
